ArticleThe Journal of antimicrobial chemotherapy2020
Is there a role for tedizolid in the treatment of non-tuberculous mycobacterial disease?
Article in The Journal of antimicrobial chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 45 citations in OpenAlex.
- A rare invader on a cardiac stent:IDCases · 2026Article
- Pharmacodynamic evidence for tedizolid use inIJTLD open · 2026Article
- Review of the Canadian Nontuberculous Mycobacterial Disease Landscape-Challenges and Opportunities.Tropical medicine and infectious disease · 2025Review
- ThePeerJ · 2025Review
- Growing from common ground: nontuberculous mycobacteria and bronchiectasis.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Review
- Tackling Nontuberculous Mycobacteria by Repurposable Drugs and Potential Leads from Natural Products.Current topics in medicinal chemistry · 2024Review
- Intracellular and in vivo activities of oxazolidinone drugs against Mycobacterium avium complex infection.Scientific reports · 2023Article
- Article
- Side-by-Side Profiling of Oxazolidinones to Estimate the Therapeutic Window against Mycobacterial Infections.Antimicrobial agents and chemotherapy · 2023Article
- Contemporary Pharmacotherapies for Nontuberculosis Mycobacterial Infections: A Narrative Review.Infectious diseases and therapy · 2023Review
- Omadacycline for the treatment ofIDCases · 2023Article
- Non-tuberculous mycobacterial disease: progress and advances in the development of novel candidate and repurposed drugs.Frontiers in cellular and infection microbiology · 2023Review
- A Novel Leucyl-tRNA Synthetase Inhibitor, MRX-6038, Expresses Anti-Mycobacterium abscessus ActivityAntimicrobial agents and chemotherapy · 2022Article
- In vitro assessment of 17 antimicrobial agents against clinical Mycobacterium avium complex isolates.BMC microbiology · 2022Article
- ERS International Congress 2021: highlights from the Respiratory Infections Assembly.ERJ open research · 2022Review
- Management ofEuropean respiratory review : an official journal of the European Respiratory Society · 2022Review
- In vitro Susceptibility of Nontuberculous Mycobacteria to Tedizolid.Infection and drug resistance · 2022Article
- Prolonged tedizolid use in cutaneous non-tuberculous mycobacterial infection.Journal of clinical tuberculosis and other mycobacterial diseases · 2021Article
- Pipeline of anti-Mycobacterium abscessus small molecules: Repurposable drugs and promising novel chemical entities.Medicinal research reviews · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPulmonary infections caused by non-tuberculous mycobacteria (NTM) are hard to treat and have low cure rates despite intensive multidrug therapy.
objectivesTo assess the feasibility of tedizolid, a new oxazolidinone, for the treatment of Mycobacterium avium and Mycobacterium abscessus.
methodsWe determined MICs of tedizolid for 113 isolates of NTM. Synergy with key antimycobacterial drugs was assessed using the chequerboard method and calculation of the FIC index (FICI). We performed time-kill kinetics assays of tedizolid alone and combined with amikacin for M. abscessus and with ethambutol for M. avium. Human macrophages were infected with M. abscessus and M. avium and subsequently treated with tedizolid; intracellular and extracellular cfu were quantified over time.
resultsNTM isolates generally had a lower MIC of tedizolid than of linezolid. FICIs were lowest between tedizolid and amikacin for M. abscessus (FICI = 0.75) and between tedizolid and ethambutol for M. avium (FICI = 0.72). Clarithromycin and tedizolid showed initial synergy, which was abrogated by erm(41)-induced macrolide resistance (FICI = 0.53). Tedizolid had a weak bacteriostatic effect on M. abscessus and combination with amikacin slightly prolonged its effect. Tedizolid had concentration-dependent activity against M. avium and its efficacy was enhanced by ethambutol. Both combinations had a concentration-dependent synergistic effect. Tedizolid could inhibit the intracellular bacterial population of both M. avium and M. abscessus.
conclusionsTedizolid should be further investigated in pharmacodynamic studies and clinical trials for M. avium complex pulmonary disease. It is less active against M. abscessus, but still promising.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.